查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1391954

腫瘤微環境市場：按癌症類型、標靶、治療方法、最終用戶和地區分類

Tumor Microenvironment Market, By Cancer Type, Target, Therapy (Monoclonal Antibodies, Cytokines, Cancer Vaccines, Oncolytic Viruses, Adoptive Cell Therapies & Others), End User (Biopharmaceutical Companies, Hospitals, & Others), Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年全球腫瘤微環境市場規模為14.7億美元，預計2030年將達34.3億美元，2023-2030年年複合成長率為12.9%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 14.7億美元
實績資料 2018-2021 預測期 2023-2030
預測期年複合成長率 12.90% 2030年市場規模預測 34.3億美元
圖 1. 2023 年全球腫瘤微環境市場佔有率(%)（按地區）
腫瘤微環境市場-IMG1

腫瘤微環境是一個複雜的生態系統，由各種細胞和非細胞成分組成，它們相互作用，在腫瘤的發生和進展中發揮重要作用。這些成分包括免疫細胞、纖維母細胞、血管、細胞外基質和訊號分子。了解腫瘤微環境對於開發有效治療癌症的標靶治療至關重要。近年來，隨著我們認知到癌細胞與其周圍環境之間動態相互作用的重要性，腫瘤微環境的研究引起了廣泛的關注。現在已經清楚，腫瘤微環境影響血管生成、免疫反應、轉移和抗藥性等多種過程。

市場動態：

由於多種因素，腫瘤微環境市場預計在未來幾年將顯著成長。主要因素之一是全世界癌症發生率的增加。根據世界衛生組織 (WHO) 2020 年的數據，癌症是全球主要死亡原因之一，每年報告約 1,000 萬新患者和 600 萬人死亡。這增加了對了解和治療癌症的先進方法的需求，從而推動了市場成長。

然而，高昂的研發成本、嚴格的監管要求以及在腫瘤微環境研究中使用動物模型的倫理問題等因素可能會抑制市場成長。此外，熟練專家的有限和調查方法缺乏標準化也可能對市場成長構成挑戰。

儘管有這些挑戰，腫瘤微環境市場仍存在巨大的成長機會。多光子顯微鏡和活體成像等成像技術的進步使研究人員能夠即時、高解析度地研究腫瘤微環境。此外，個人化醫療的出現和對精準腫瘤學的日益關注創造了對能夠洞察腫瘤微環境的生物標記的需求，進一步推動市場成長。

此外，市場參與企業正在採取聯盟等無機策略，預計這將在預測期內促進全球腫瘤微環境市場的成長。例如，2023年3月20日，德國生物技術公司BioNTech SE與臨床階段生物製藥公司OncoC4, Inc.宣布，OncoC4的下一代抗CTLA-4單株抗體候選物ONC-392宣布已達成合作協議。全球獨家許可和合作協議，用於開發和商業化該藥物作為多種癌症適應症的單一療法或聯合治療。 CTLA-4是一種透過多種機制抑制免疫細胞活性的分子。 OncoC4 的 CTLA-4 候選抗體 ONC-392 旨在消除腫瘤微環境中的免疫抑制 T 細胞（調節性 T 細胞，「Treg」）並保留健康組織中的 Tregs。

本研究的主要特點

  • 本報告詳細分析了全球腫瘤微環境市場，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
  • 它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
  • 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
  • 它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球腫瘤微環境市場的主要企業。
  • 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出資訊的決策。
  • 全球腫瘤微環境市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球腫瘤微環境市場的各種策略矩陣，將有助於相關人員做出決策。

目錄

第1章 研究目的與假設

  • 研究目標
  • 假設
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

  • 市場動態
    • 癌症發生率增加
    • 與試劑相關的高成本
    • 介紹人工智慧和機器學習
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/核准
  • PEST分析
  • 波特的分析
  • 併購場景

第4章腫瘤微環境市場－冠狀病毒（COVID-19）大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第5章腫瘤微環境市場，依癌症類型，2018-2030

  • 介紹
  • 肺癌
  • 大腸直腸癌
  • 乳癌
  • 攝護腺癌
  • 膀胱癌
  • 其他（黑色素瘤、腎臟癌、卵巢癌等）

第6章腫瘤微環境市場，依目標，2018-2030

  • 介紹
  • T細胞
  • 腫瘤相關巨噬細胞
  • 骨髓源性抑制細胞
  • 癌症相關纖維母細胞
  • 調節性T細胞
  • 其他（腫瘤相關嗜中性白血球、樹突狀細胞等）

第7章腫瘤微環境市場，依治療方法，2018-2030

  • 介紹
  • 單株抗體
  • 細胞因子
  • 癌症疫苗
  • 溶瘤病毒
  • 過繼性細胞療法
  • 其他（基因治療、免疫調節劑、檢查點抑制劑等）

第 8 章腫瘤微環境市場，依最終使用者分類，2018-2030 年

  • 介紹
  • 生物製藥公司
  • 醫院
  • 診斷實驗室
  • 研究機構
  • 受託研究機構（CRO）
  • 其他（學術機構等）

第9章腫瘤微環境市場，依地區，2018-2030

  • 介紹
  • 北美洲
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 歐洲其他地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 東南亞國協
  • 其他亞太地區
  • 中東和非洲
  • 海灣合作理事會國家
  • 以色列
  • 南非
  • 北非
  • 中部非洲
  • 其他中東地區

第10章競爭形勢

  • Thermo Fisher Scientific
  • Illumina
  • Danaher Corporation
  • Merck KGaA
  • BD Biosciences
  • Promega Corporation
  • Bio-Techne Corporation
  • Bio-Rad Laboratories
  • F.Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Sartorius AG
  • PerkinElmer
  • Miltenyi Biotec
  • Cell Signaling Technology
  • BioLegend
  • Abcam
  • Takara Bio
  • Fluidigm Corporation
  • NanoString Technologies
  • 10x Genomics
  • Bethyl Laboratories

第11章 章節

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI6238

The global tumor microenvironment market size was valued at US$ 1.47 Bn in 2023 and is expected to reach US$ 3.43 Bn by 2030, grow at a compound annual growth rate (CAGR) of 12.9% from 2023 to 2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 1.47 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 12.90% 2030 Value Projection: US$ 3.43 Bn
Figure 1. Global Tumor Microenvironment Market Share (%), By Region, 2023
Tumor Microenvironment Market - IMG1

The tumor microenvironment is a complex ecosystem consisting of various cellular and non-cellular components that interact with each other and play a crucial role in tumor development and progression. These components include immune cells, fibroblasts, blood vessels, the extracellular matrix, and signaling molecules. Understanding the tumor microenvironment is essential for developing targeted therapies that can effectively treat cancer. The study of the tumor microenvironment has gained significant attention in recent years, as researchers have realized the importance of this dynamic interaction between tumor cells and their surroundings. It is now evident that the tumor microenvironment can influence various processes, such as angiogenesis, immune response, metastasis, and drug resistance.

Market Dynamics:

The tumor microenvironment market is expected to witness significant growth in the coming years, driven by several factors. One of the major drivers is the increasing incidence of cancer worldwide. According to the World Health Organization (WHO), 2020, cancer is one of the leading causes of death globally, with approximately 10 million new cases and 6 million deaths reported annually. This has led to a substantial demand for advanced methods to understand and treat cancer, thereby driving market growth.

However, market growth can be restrained by factors, such as the high cost of research and development, stringent regulatory requirements, and ethical concerns related to the use of animal models in tumor microenvironment studies. Additionally, the limited availability of skilled professionals and the lack of standardization in research methodologies can pose challenges to market growth.

Despite these challenges, the tumor microenvironment market offers significant opportunities for growth. Technological advancements in imaging techniques, such as multiphoton microscopy and intravital imaging, have enabled researchers to study the tumor microenvironment in real-time and high resolution. Moreover, the emergence of personalized medicine and the increasing focus on precision oncology have created a demand for biomarkers that can provide insights into the tumor microenvironment, further driving market growth.

Moreover, market players are engaged in conducting inorganic strategies such as collaborations, and this is expected to increase the growth of the global tumor microenvironment market over the forecast period. For instance, on March 20, 2023, BioNTech SE, a German biotechnology company and OncoC4, Inc., a clinical-stage biopharmaceutical company, announced that they had entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4's next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications. CTLA-4 is a molecule that inhibits the activity of immune cells via various mechanisms. OncoC4's CTLA-4 antibody candidate, ONC-392, aims to delete immunosuppressive T cells (regulatory T cells, "Tregs") in the tumor microenvironment but spare Tregs in healthy tissues.

Key features of the study:

  • This report provides in-depth analysis of the global tumor microenvironment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global tumor microenvironment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Thermo Fisher Scientific, Illumina, Danaher Corporation, Merck KGaA , BD Biosciences, Promega Corporation, Bio-Techne Corporation , Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, QIAGEN N.V., Sartorius AG, PerkinElmer, Miltenyi Biotec, Cell Signaling Technology, BioLegend, Abcam, Takara Bio, Fluidigm Corporation, NanoString Technologies, 10x Genomics, and Bethyl Laboratories
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global tumor microenvironment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor microenvironment market

Detailed Segmentation:

  • By Cancer Type
    • Lung Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Prostate Cancer
    • Bladder Cancer
    • Others (Melanoma, Kidney cancer, Ovarian cancer etc.)
  • By Target
    • T Cells
    • Tumor-Associated Macrophages
    • Myeloid-Derived Suppressor Cells
    • Cancer-Associated Fibroblasts
    • Regulatory T Cells
    • Others (Tumor-associated neutrophils, Dendritic cells etc.)
  • By Therapy:
    • Monoclonal Antibodies
    • Cytokines
    • Cancer Vaccines
    • Oncolytic Viruses
    • Adoptive Cell Therapies
    • Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.)
  • By End User
    • Biopharmaceutical Companies
    • Hospitals
    • Diagnostic Laboratories
    • Research Institutes
    • Contract Research Organizations (CROs)
    • Others (Academic Institutes and Others)
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Key Players
    • Thermo Fisher Scientific
    • Illumina
    • Danaher Corporation
    • Merck KGaA
    • BD Biosciences
    • Promega Corporation
    • Bio-Techne Corporation
    • Bio-Rad Laboratories
    • F.Hoffmann-La Roche Ltd
    • QIAGEN N.V.
    • Sartorius AG
    • PerkinElmer
    • Miltenyi Biotec
    • Cell Signaling Technology
    • BioLegend
    • Abcam
    • Takara Bio
    • Fluidigm Corporation
    • NanoString Technologies
    • 10x Genomics
    • Bethyl Laboratories

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Tumor Microenvironment, By Cancer Type
    • Market Tumor Microenvironment, By Target
    • Market Tumor Microenvironment, By Therapy
    • Market Tumor Microenvironment, By End User
    • Market Tumor Microenvironment, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing cancer prevalence
    • High costs associated with reagents
    • Adoption of AI and machine learning
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Tumor Microenvironment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Tumor Microenvironment Market , By Cancer Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Bladder Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others (Melanoma, Kidney cancer, Ovarian cancer etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Tumor Microenvironment Market , By Target, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • T Cells
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Tumor-associated Macrophages
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Myeloid-Derived Suppressor Cells
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Cancer-Associated Fibroblasts
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Regulatory T Cells
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others (Tumor-associated neutrophils, Dendritic cells etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Tumor Microenvironment Market , By Therapy, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Monoclonal Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Cytokines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Cancer Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Oncolytic Viruses
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Adoptive Cell Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Tumor Microenvironment Market , By End User, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Biopharmaceutical Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Contract Research Organizations (CROs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others (Academic Institutes and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Tumor Microenvironment Market , By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Country 2018 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
    • U.S.
    • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • GCC Countries
  • Israel
  • South Africa
  • North Africa
  • Central Africa
  • Rest of Middle East

10. Competitive Landscape

  • Thermo Fisher Scientific
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Illumina
  • Danaher Corporation
  • Merck KGaA
  • BD Biosciences
  • Promega Corporation
  • Bio-Techne Corporation
  • Bio-Rad Laboratories
  • F.Hoffmann-La Roche Ltd
  • QIAGEN N.V.
  • Sartorius AG
  • PerkinElmer
  • Miltenyi Biotec
  • Cell Signaling Technology
  • BioLegend
  • Abcam
  • Takara Bio
  • Fluidigm Corporation
  • NanoString Technologies
  • 10x Genomics
  • Bethyl Laboratories
  • Analyst Views

11. Section

  • Research Methodology
  • About us